Physicians' Academy for Cardiovascular Education

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD - Advocate Heart Institute, Naperville, IL, USA

Video navigation menu

  • Effects of SGLT2 inhibitors 00:21
  • SGLT2 function in the early proximal tubule 01:32
  • SGLT2i and BP effects: changes in intravascular volume 05:38
  • Potential mechanisms of SGLT2i 07:34
  • Clinical trials with SGLT2i 10:09

What is the potential mechanism of blood pressure lowering by SGLT2i?

  • A. Decrease in red cell mass
  • B. Decrease in plasma volume
  • C. Increase in fluid retention by the interstitial compartment
  • D. Increase in skin sodium content
Show the correct answer.

Educational information

This lecture by Maria Rosa Costanzo was part of the EBAC-accredited symposium "Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i" held during the virtual ERA EDTA 2020 meeting.


Maria Rosa Costanzo, MD is a cardiologist and medical director for heart failure research at the Advocate Heart Institute in Naperville, IL, USA.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of the presentation

Share this page with your colleagues and friends: